PTC Therapeutics Inc. | Mutual Funds
Mutual Funds that own PTC Therapeutics Inc.
Janus Capital Funds Plc - Global Life Sciences Fund
9,919,000
19.75%
9,919,000
16.25%
12/31/2017
SPDR S&P Biotech ETF
1,800,905
3.59%
4,632
1.28%
09/06/2018
Fidelity Select Biotechnology Portfolio
1,185,345
2.36%
118,500
0.54%
07/31/2018
Vanguard Total Stock Market Index Fund
1,095,208
2.18%
0
0.01%
07/31/2018
iShares Russell 2000 ETF
947,499
1.89%
-507
0.08%
09/06/2018
Vanguard Small Cap Index Fund
555,919
1.11%
7,961
0.02%
07/31/2018
iShares Nasdaq Biotechnology ETF
538,241
1.07%
-7,035
0.23%
09/06/2018
Vanguard Extended Market Index Fund
509,018
1.01%
4,700
0.03%
07/31/2018
iShares Russell 2000 Growth ETF
439,630
0.88%
0
0.16%
09/06/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
350,913
0.7%
-120,087
0.68%
12/31/2017
| Address |
100 Corporate Court
South Plainfield New Jersey 07080
United States
|
|
Employees
|
- |
| Website |
http://www.ptcbio.com |
| Updated |
07/08/2019 |
| PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. It is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. |
